Pavel, MarianneGross, David JBenavent, MartaPerros, PetrosSrirajaskanthan, RajWarner, Richard R PKulke, Matthew HAnthony, Lowell BKunz, Pamela LHörsch, DieterWeickert, Martin OLapuerta, PabloJiang, WenjunKassler-Taub, KennethWason, SumanFleming, RosannaFleming, DouglasGarcia-Carbonero, Rocio2023-01-252023-01-252018-01-12http://hdl.handle.net/10668/12005Telotristat ethyl, a tryptophan hydroxylase inhibitor, was efficacious and well tolerated in the phase 3 TELESTAR study in patients with carcinoid syndrome (CS) experiencing ≥4 bowel movements per day (BMs/day) while on somatostatin analogs (SSAs). TELECAST, a phase 3 companion study, assessed the safety and efficacy of telotristat ethyl in patients with CS (diarrhea, flushing, abdominal pain, nausea or elevated urinary 5-hydroxyindoleacetic acid (u5-HIAA)) withenAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/5-HIAAcarcinoid syndromemetastatic neuroendocrine tumorserotoninsomatostatin analogAdultAgedAged, 80 and overDiarrheaDouble-Blind MethodFemaleHumansHydroxyindoleacetic AcidMaleMalignant Carcinoid SyndromeMiddle AgedPhenylalaninePyrimidinesSomatostatinTreatment Outcomeresearch article29330194open access10.1530/ERC-17-04551479-6821PMC5811631https://erc.bioscientifica.com/downloadpdf/journals/erc/25/3/ERC-17-0455.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811631/pdf